Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMedical University of Lublin
About this trial
Mastocytosis is very rare and highly heterogeneous group of disorders, characterized by the accumulation of clonal mast cells which can infiltrate several organs and tissues.
Bones are the most frequent localization of systemic mastocytosis. The aim of our research was to explain the potential role of sclerostin in the pathogenesis of bone disease in mastocytosis.
Eligibility criteria
Qualifiers
Age > 18 years
Mastocytosis defined according to WHO criteria
Known KIT mutation status
Disqualifiers
History of organ transplant
Inability to give informed consent
Pregnancy, Breastfeeding
Vulnerable Patient, defined as: patient with another uncontrolled severe disease; patient under juridical protection
Trial design
Treatments tested in this trial
- SCLEROSTIN
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov